Viktor Grunwald, MD, PhD, reviews the efficacy findings of lenvatinib combined with pembrolizumab and sunitinib for the treatment of patients with advanced renal cell carcinoma.
Viktor Grünwald, MD, PhD, of Hannover Medical School, reviews the efficacy findings of lenvatinib (Lenvima) combined with pembrolizumab (Keytruda) and sunitinib (Sutent) for the treatment of patients with advanced renal cell carcinoma (RCC) presented during the 2021 American Society of Clinical Oncology Annual Meeting.
In the CLEAR study, investigators noticed an impact in efficacy that was irrespective of the adverse event profile. In terms of progression-free survival, the results were similar in patients who were considered to have favorable risk and those who had at least 1 risk parameter. Grunwald also states that the highest complete responders to the combination were those with favorable risk.
The findings related to the difference between patients with favorable-risk and high-risk advanced RCC are descriptive, notes Grunwald and require further research.